MAPT and Alzheimer disease: Zileuton, an anti-inflammatory compound, inhibits LOX5 and decreases γ-secretase, Aβ, and tau after three months of treatment in a 3xTg mouse AD model (Di Meco et al., 2014), demonstrating its broad prospects for clinical use.